NEXGEL New Strategic Partner
PRESS RELEASE NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete…
Mark ChapmanApril 21, 2026
Early Outcomes from the RENEW Modified Platform Trial of Cellular, Acellular, and Matrix-Like Product Interventions for Diabetic Foot Ulcers
RESEARCH Early Outcomes from the RENEW Modified Platform Trial of Cellular, Acellular, and Matrix-Like Product…
Mark ChapmanApril 11, 2026
Sequence LifeScience, Inc. Receives IRB Approval for a Novel Matched Controls Clinical Trial Targeting Diabetic Foot Ulcers (DFUs)
PRESS RELEASE Sequence LifeScience, Inc. Receives IRB Approval for a Novel Matched Controls Clinical Trial…
Mark ChapmanApril 11, 2026
Sequence LifeScience Enrolls First Patient in Clinical Trial Evaluating Placental Membrane Grafts for Diabetic Foot Ulcers
PRESS RELEASE Sequence LifeScience Enrolls First Patient in Clinical Trial Evaluating Placental Membrane Grafts for…
Mark ChapmanApril 11, 2026
Evaluating the efficacy of placental-derived allograft in managing non-healing pressure ulcers
RESEARCH ARTICLE Evaluating the efficacy of placental-derived allograft in managing non-healing pressure ulcers Thomas Serena,…
Mark ChapmanApril 11, 2026
Efficacy of placental derived allografts and standard of care in the treatment of nonhealing diabetic foot ulcers using matched controls: a randomized controlled trial
RESEARCH ARTICLE Efficacy of placental derived allografts and standard of care in the treatment of…
Mark ChapmanApril 11, 2026
